Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

    NEXT STORY
    Resverlogix Confirms a Significant Corporate Advancement Establishing Apabetalone as a Potential Blockbuster Combination Drug in High-risk Diabetes Patients with CVD
    PREV STORY
    Vir Biotechnology to Provide Pipeline Update at 38th Annual J.P. Morgan Healthcare Conference
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Covetrus Announces Financial Results for Second Quarter of 2020

    author_avatar
    NASDAQ Market News

    PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune®-based COVID-19 Vaccine

    author_avatar
    NASDAQ Market News

    The American College of Rheumatology Recommends Biosimilar Use in New White Paper

    Atlanta, Feb. 07, 2018 (GLOBE NEWSWIRE) -- The American College of Rheumatology (ACR) has ...

    author_avatar
    NASDAQ Market News